PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis

Trends in colorectal cancer in the south of the Netherlands 1975–2007: Rectal cancer survival levels with colon cancer survival

(2010) Valery Lemmens et al.   ACTA ONCOLOGICA

Improved survival of colon cancer due to improved treatment and detection: a nationwide population-based study in The Netherlands 1989-2006

(2010) L. N. van Steenbergen et al.   ANNALS OF ONCOLOGY

The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients

(2010) A. Fariña-Sarasqueta et al.   ANNALS OF ONCOLOGY

Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer

(2010) Daniel J. Sargent et al.   JOURNAL OF CLINICAL ONCOLOGY

Discussion

(2010)   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

Inhibitors of phosphatidylinositol-3-kinase in cancer therapy

(2010) Nathan T. Ihle et al.   MOLECULAR ASPECTS OF MEDICINE

Status of PI3K inhibition and biomarker development in cancer therapeutics

(2009) B. Markman et al.   ANNALS OF ONCOLOGY

Functional differences between two classes of oncogenic mutation in the PIK3CA gene

(2009) Claire Chaussade et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Differential Enhancement of Breast Cancer Cell Motility and Metastasis by Helical and Kinase Domain Mutations of Class IA Phosphoinositide 3-Kinase

(2009) H. Pang et al.   CANCER RESEARCH

PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer

(2009) H. Prenen et al.   CLINICAL CANCER RESEARCH

Clinical implications of microsatellite instability in sporadic colon cancers

(2009) Frank A Sinicrope et al.   CURRENT OPINION IN ONCOLOGY

PIK3CAMutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer

(2009) Shuji Ogino et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial

(2009) Arnaud D. Roth et al.   JOURNAL OF CLINICAL ONCOLOGY

PIK3CA Exon 20 Mutation is Independently Associated with a Poor Prognosis in Breast Cancer Patients

(2008) Yuen-Liang Lai et al.   ANNALS OF SURGICAL ONCOLOGY

BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: Primary or secondary genetic events in colorectal carcinogenesis?

(2008) Sérgia Velho et al.   BMC CANCER

Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers

(2008) Ludovic Barault et al.   INTERNATIONAL JOURNAL OF CANCER

Class I PI3K in oncogenic cellular transformation

(2008) L Zhao et al.   ONCOGENE

Helical domain and kinase domain mutations in p110  of phosphatidylinositol 3-kinase induce gain of function by different mechanisms

(2008) L. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA